The inaugural OU Health Cardiovascular Symposium will be held this Saturday May 9th at Samis Auditorium Children’s Hospital. We will have world-renowned speakers, OUH faculty and interactive panels. Registration is free and CME available. Don’t miss it!
ouhealth.com/events-calendar…
☢️ Radiation exposure and orthopedic strain remain major risks in the #CathLab. SCAI’s new Radiation and Occupational Safety Resource Center brings together toolkits, clinical documents, and on-demand education to help teams create safer environments.
Explore the resource center ➡️ scai.org/clinical-practice/q…#SCAIWellness#CardioX#InterventionalCardiology
The data continues to support intensive lipid lowering therapy. As had been said by subject experts in the recent past, implementation is the biggest next step!
#CardioX#ACCFIT#LowerIsBetter
Among patients with atherosclerotic cardiovascular disease, targeting an LDL cholesterol level below 55 mg per deciliter led to a lower 3-year risk of cardiovascular events than targeting a level below 70 mg per deciliter. Full Ez-PAVE trial results and Research Summary: nejm.org/doi/full/10.1056/NE…
ALT The New England Journal of Medicine
LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease
A Research Summary based on Lee Y-J et al. | 10.1056/NEJMoa2600283 | Published on March 28, 2026
Visual representations of the patients in the trial and the treatments they were assigned.
Read the full Research Summary at NEJM.org.
OKC Chapter of ACC meeting 2026
starts with Dr. Barac @AnaBaracCardio addressing Cardio-Oncology in 2026: Roadmap for Clinical Care and Service-Line Collaboration
Big shoutout to our amazing Social Media Ambassadors! 🎉
Your energy, expertise, and dedication helped make #ACC26 truly unforgettable. Thank you for sparking meaningful conversations, sharing your insights, and keeping the momentum alive 👏👏👏 @ACCinTouch
HOST-EXAM trial 10-year results: Clopidogrel monotherapy is superior to aspirin for chronic maintenance after PCI, significantly reducing both thrombotic and bleeding events. #ACC26 View slides here: clinicaltrialresults.org/wp-…
6/
➡️ All cause mortality at 30d: HR 0.33 (p value 0.08 and CI crossing 1)
➡️ All cause mortality at 365d: HR 0.76 (p value 0.51)
➡️ CV mortality at 30d: similar to all cause
➡️ CV mortality at 365d: HR 0.74 (p value 0.49)